Pages that link to "Q34437163"
Jump to navigation
Jump to search
The following pages link to Mechanism of action of trastuzumab and scientific update (Q34437163):
Displaying 50 items.
- Defining the sister rat mammary tumor cell lines HH-16 cl.2/1 and HH-16.cl.4 as an in vitro cell model for Erbb2 (Q21134904) (← links)
- Epidermal growth factor receptor blockers for the treatment of ovarian cancer (Q24236143) (← links)
- Epidermal growth factor receptor blockers for the treatment of ovarian cancer (Q24240523) (← links)
- Epidermal growth factor receptor blockers for the treatment of ovarian cancer (Q24240840) (← links)
- IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistance (Q24309891) (← links)
- Quercetin-induced ubiquitination and down-regulation of Her-2/neu (Q24646978) (← links)
- The antitumor immune response in HER-2 positive, metastatic breast cancer patients. (Q24796706) (← links)
- Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It (Q26752780) (← links)
- Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition (Q28829301) (← links)
- Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells (Q30412654) (← links)
- The role of trastuzumab in early stage breast cancer: current data and treatment recommendations (Q31120100) (← links)
- Applications of transfected cell microarrays in high-throughput drug discovery. (Q33185812) (← links)
- Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells. (Q33284158) (← links)
- A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects (Q33599885) (← links)
- CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient (Q33728102) (← links)
- Activation of the unfolded protein response bypasses trastuzumab-mediated inhibition of the PI-3K pathway (Q33880386) (← links)
- A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression (Q33991817) (← links)
- Herceptin Conjugates Linked by EDC Boost Direct Tumor Cell Death via Programmed Tumor Cell Necrosis (Q33997021) (← links)
- Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo (Q34103311) (← links)
- CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer (Q34176395) (← links)
- Targeting HER2 in breast cancer: overview of long-term experience (Q34272044) (← links)
- Development of an ErbB‐overexpressing A‐431 Optical Reporting Tumor Xenograft Model to Assess Targeted Photodynamic Therapy Regimens (Q34349345) (← links)
- Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels (Q34493886) (← links)
- The ErbB receptor family: a therapeutic target for cancer (Q34583857) (← links)
- A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01). (Q34635509) (← links)
- Targeted immunotherapy of cancer: development of antibody-induced cellular immunity. (Q35084986) (← links)
- Immunology and immunotherapy of colorectal cancer (Q35097710) (← links)
- Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence (Q35208201) (← links)
- Trastuzumab-induced cardiac dysfunction: A 'dual-hit' (Q35532125) (← links)
- The anticancer effect of probiotic Bacillus polyfermenticus on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition (Q35571641) (← links)
- Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways (Q35605824) (← links)
- HER2 therapy: molecular mechanisms of trastuzumab resistance. (Q35633712) (← links)
- A structural perspective on the regulation of the epidermal growth factor receptor (Q35674768) (← links)
- Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer (Q35684440) (← links)
- Managing high-risk breast cancer (Q35819307) (← links)
- Structure and function of the epidermal growth factor (EGF/ErbB) family of receptors (Q35925840) (← links)
- Treatment of HER2-positive metastatic breast cancer following initial progression (Q36275971) (← links)
- Resistance to Trastuzumab in Breast Cancer. (Q36318226) (← links)
- Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer (Q36472437) (← links)
- The ErbB2 signaling network as a target for breast cancer therapy (Q36583512) (← links)
- Trastuzumab-Resistant Luminal B Breast Cancer Cells Show Basal-Like Cell Growth Features Through NF-κB-Activation (Q36630127) (← links)
- Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment (Q36648369) (← links)
- IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production (Q36671364) (← links)
- The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis (Q36677504) (← links)
- The mitochondrial transport protein SLC25A43 affects drug efficacy and drug-induced cell cycle arrest in breast cancer cell lines (Q36753310) (← links)
- Trastuzumab: triumphs and tribulations (Q36832109) (← links)
- Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer (Q36914142) (← links)
- High serum HTATIP2/TIP30 level in serous ovarian cancer as prognostic or diagnostic marker (Q36964290) (← links)
- Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer. (Q37109776) (← links)
- Structure based antibody-like peptidomimetics (Q37148681) (← links)